Diffuse Large B Cell Lymphoma Clinical Trials

47 recruiting

Diffuse Large B Cell Lymphoma Trials at a Glance

74 actively recruiting trials for diffuse large b cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 31 trials, with the heaviest enrollment activity in New York, Shanghai, and Beijing. Lead sponsors running diffuse large b cell lymphoma studies include Ruijin Hospital, Memorial Sloan Kettering Cancer Center, and Abramson Cancer Center at Penn Medicine.

Browse diffuse large b cell lymphoma trials by phase

Treatments under study

About Diffuse Large B Cell Lymphoma Clinical Trials

Looking for clinical trials for Diffuse Large B Cell Lymphoma? There are currently 47 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Large B Cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Large B Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 74 trials

Recruiting
Phase 1

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca227 enrolled27 locationsNCT04594642
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Early Phase 1

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaB-cell Non Hodgkin Lymphoma (NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24 enrolled1 locationNCT07548697
Recruiting
Phase 1Phase 2

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 2

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Diffuse Large B Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute27 enrolled1 locationNCT05757219
Recruiting
Phase 1

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 2

CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

Diffuse Large B Cell Lymphoma
Washington University School of Medicine36 enrolled1 locationNCT06687772
Recruiting
Phase 1Phase 2

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Not Applicable

A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL

Diffuse Large B Cell LymphomaRadiotherapyCAR-T+1 more
Peking Union Medical College Hospital20 enrolled1 locationNCT05514327
Recruiting

Glofitamab in Chinese Patients With R/R DLBCL

DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital20 enrolled1 locationNCT06481826
Recruiting
Phase 2

CAR-T Followed by Bispecific Antibodies

DLBCL - Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Abramson Cancer Center at Penn Medicine42 enrolled2 locationsNCT04889716
Recruiting
Phase 1

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Diffuse Large B Cell LymphomaAcute Lymphoblastic LeukemiaMultiple Myeloma+3 more
Joshua Sasine, MD, PhD20 enrolled1 locationNCT05887167
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+4 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Recruiting
Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Phase 1

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

Diffuse Large B Cell LymphomaAcute Lymphoblastic Leukemia
University of Utah10 enrolled1 locationNCT06227026
Recruiting
Phase 2

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Diffuse Large B Cell Lymphoma
Sun Yat-sen University42 enrolled2 locationsNCT06517511
Recruiting
Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting
Phase 1

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting
Phase 1Phase 2

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 1

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.30 enrolled1 locationNCT07368270